Scinai to acquire Pincell for its rare skin disease drug PC111
The acquisition includes Pincell’s lead candidate, PC111, a fully human monoclonal antibody targeting rare and severe skin diseases, without suppressing the immune system
News
Genmab’s Tivdak approved in Japan to treat cervical cancer
Bio-Thera partners with Dr. Reddy’s for commercialisation of proposed biosimilars
Merck’s pneumococcal vaccine Capvaxive approved in EU
Exelixis obtains expanded FDA approval for Cabometyx to treat NET
Merck, Hengrui Pharma sign licensing agreement for HRS-5346
Character Bio secures $93m funding to advance precision medicine for AMD
Kelun-Biotech’s SKB107 gains approval for bone metastases clinical trials in China
